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ABSTRACT: Mycobacterium tuberculosis (Mtb) and Mycobac-
terium smegmatis (Msmeg) can grow on cholesterol as the sole
carbon source. In Mtb the utilization of cholesterol can be
initiated by CYP125A1 or CYP142A1 and in Msmeg by the
orthologous CYP125A3 and CYP142A2. Double knockout of
the two enzymes in Mtb prevents its growth on cholesterol,
but the double knockout ofMsmeg is still able to grow, albeit at
a slower rate. We report here that Msmeg has a third enzyme,
CYP125A4, that also oxidizes cholesterol, although it has a
much higher activity for the oxidation of 7α-hydroxycholester-
ol. The ability of Msmeg CYP125A4 (and Mtb CYP125A1) to
oxidize 7α-hydroxycholesterol is due, at least in part, to the
presence of a smaller amino acid side chain facing C-7 of the sterol substrate than in CYP125A3. The ability to oxidize 7-
substituted steroids broadens the range of sterol carbon sources for growth, but even more importantly in Mtb, additional
biological effects are possible due to the potent immunomodulatory activity of 7α,26-dihydroxycholesterol.
Mycobacterium tuberculosis (Mtb) is the causative agent of
tuberculosis, a disease that the World Health Organization
estimates kills 1.3 million people annually.1,2 During infection,
Mtb takes up residence in the phagosomes of host macro-
phages. To survive and replicate in this nutritionally poor
environment, Mtb has evolved pathways to utilize host-derived
nutrients. Cholesterol is one such abundant intracellular
molecule that Mtb can import and degrade either for energy
or as a biosynthetic precursor.1,2 Disruption of the cholesterol
metabolic pathway leads to attenuation in models of infection
and loss of the ability to grow in vitro on cholesterol as a sole
carbon source, clearly indicating the importance of the
availability of cholesterol to the intracellular viability of the
pathogen as well as the potential for targeting this pathway for
the development of novel therapeutic agents.1,3−6 The first and
enabling step in the cholesterol degradation pathway is the
oxidation of the cholesterol alkyl side chain to a carboxylic acid
by cytochromes P450 (CYP) 125A1 (Rv3545c) and 142A1
(Rv3518c), which can then be further catabolized via a β-
oxidation pathway.7−9 This pathway is conserved in Rhodo-
coccus jostii,10 as well as Mycobacterium smegmatis (Msmeg), a
soil-dwelling nonpathogenic relative of Mtb, where it is under
the control of the TetR-like repressor KstR. In Msmeg,
C Y P 1 2 5 A 3 (MSMEG_ 5 9 9 5 ) a n d CY P 1 4 2 A 2
(MSMEG_5918) serve as orthologs for the oxidation of
cholesterol at C-26.11−13 However, unlike its Mtb relative, the
Msmeg Δcyp125a3/Δcyp142a2 double mutant retains its ability
to utilize cholesterol as a carbon source for growth in vitro.14
To investigate this difference in cholesterol metabolism, we
first examined CYP189A1 (MSMEG_4829), a cytochrome
P450 of unknown function, previously shown to be upregulated
in response to cholesterol, although not under direct control of
the KstR regulatory pathway.15 However, as reported here, in
vitro binding and oxidation assays failed to show any activity for
this enzyme toward cholesterol, 4-cholesten-3-one, or other
structurally related compounds. Our attention then turned to
CYP125A4 (MSMEG_3524), a gene not observed to be
upregulated in response to cholesterol but that shares
approximately 65% sequence identity with CYP125A3.
Surprisingly, CYP125A4 showed only weak activity toward
cholesterol and 4-cholesten-3-one in vitro, but it had robust
activity toward 7α-hydroxy-4-cholesten-3-one, forming 7α,26-
dihydroxy-4-cholesten-3-one, a compound implicated in
immune cell migration and signaling in humans.16,17 In
contrast, CYP125A3 failed to show any activity toward this
oxysterol.
Homology modeling of CYP125A3 and CYP125A4 using the
CYP125A1 structure in complex with its substrate 4-cholesten-
3-one [Protein Data Bank (PDB) entry 2X5W], as opposed to
CYP125A3 where only the ligand free structure is available,
revealed a single amino acid difference near the cholesterol C-7
position. A bulkier Trp83 in CYP125A3, compared to the
corresponding Tyr87 in CYP125A4 (or Phe100 in CYP125A1),
protrudes farther into the active site cavity, possibly acting as a
steric block to binding of the 7α-substituted oxysterol. Site-
directed mutagenesis of the two enzymes to generate the
mutants CYP125A3 W83Y and CYP125A4 Y87W resulted in
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enzymes that effectively reversed their substrate profiles, albeit
with reduced activity relative to that of the wild-type enzymes.
A crystal structure of the CYP125A3 W83Y mutant revealed an
enlarged active site relative to that of the wild-type enzyme that
provides easier access of the 7α-substituted oxysterol to the
active site in the mutant enzyme.
This study highlights a subtle difference in the cholesterol
metabolic pathways of these two mycobacterial species, which
is relevant to the consideration of Msmeg as a model system for
the development of therapeutic agents against theMtb pathway.
■ EXPERIMENTAL PROCEDURES
Chemicals. 1,4-Cholestadiene-3-one was obtained from
Research Plus (Barnegat, NJ), and 7α-hydroxycholesterol and
7α-hydroxy-4-cholesten-3-one were from Avanti Polar Lipids
(Alabaster, AL). All other chemicals, including cholesterol,
spinach ferredoxin, spinach ferredoxin-NADP+-reductase, bo-
vine liver catalase, glucose 6-phosphate, glucose-6-phosphate
dehydrogenase, and methyl-β-cyclodextrin, were purchased
from Sigma-Aldrich (St. Louis, MO).
Protein Cloning and Mutagenesis. MSMEG_4829
(CYP189A1) and MSMEG_3524 (CYP125A4) were amplified
by polymerase chain reaction using Pfu Turbo DNA polymer-
ase (New England BioLabs), primer pairs 5′-TTTTTTCAT-
ATGGCCCAGCCCAGCACCAGTGC and 5′-AAAAAAAAG-
CTTATTATTAGTGATGGTGATGGTGATGGCGCACGA-
A C G T T G G C A T G ( C Y P 1 8 9 A 1 ) , a n d 5 ′ -
TTTTTTCATATGGTGGTCATGAGCGATAGTGC and 5′-
AAAAAAAAGCTATTATTAGTGATGGTGATGGTGATGT-
CGATCTGCCTGCGACGAC (CYP125A4), and genomic
DNA from M. smegmatis mc2155 as a template. The resulting
DNA fragments were digested using NdeI and HindIII (New
England BioLabs) and cloned into the pCWOri+ vector.18 The
expression vector used for expression of the CYP125A3 and
125A4 mutants was constructed by amplification of the
modified gene coding sequence from an existing pCWori/
cyp125A4 vector generated for this study or the pCWori/
cyp125A3 vector described previously.14 As per the instructions
of the QuikChange Lightning Site Directed Mutagenesis Kit
(Agilent), 2 μL of DpnI restriction enzyme was added to digest
the parental supercoiled dsDNA and transformed in XL-10
ultracompetent cells. The resulting plasmid was purified and
digested using NdeI and HindIII and ligated into a similarly
digested pCWori+ vector to provide the mutant expression
vector. Primers used to generate CYP125A3 W83Y were 5′-
GTCCTGCGGATACACCGGGATGGCGCCG and 5′-CGG-
CGCCATCCCGGTGTCCGCAGGAC and CYP125A4 Y87W
5′-GTCCCTTCGGGCCAACGCGGCAGCGCGGGT and 5′-
ACCGCGCTGCCGCGTTGGCCCGAAGGGAC. The en-
zyme coding region of the mutant expression vector was
sequenced for accuracy (Elim Biopharmaceuticals, Hayward,
CA).
Protein Expression, Purification, and Homology
Modeling. CYPs 189A1, 125A1, 125A3, 125A4, 125A3
W83Y, and 125A4 Y87W were expressed and purified as
previously described,14,19 with the exception of CYP125A4
Y87W, which was expressed under the same conditions with
the addition of the co-expression chaperone plasmid pTGroE
and in the presence of 20 μg/mL kanamycin.20 Briefly,
Escherichia coli DH5α cells containing the pCWori expression
vector with the gene of interest were grown at 37 °C and 250
rpm in TB medium containing 100 μg/mL ampicillin until an
OD600 of 0.7−0.8 was achieved. Expression of the proteins was
induced by the addition of 1 mM isopropyl β-D-1-
thiogalactopyranoside and 0.5 mM δ-aminolevulinic acid, and
the culture was continued for 36 h at 25 °C and 180 rpm.
Cultures were harvested by centrifugation and stored at −80
°C. Cell pellets were thawed on ice and resuspended in 50 mM
Tris-HCl (pH 7.4), 0.15 M NaCl, and 1 mM phenyl-
methanesulfonyl fluoride with agitation before the addition of
0.5 mg/mL lysozyme and 0.1 mg/mL DNase. The cells were
disrupted by sonication using a Branson sonicator (six cycles of
1 min followed by 30 s rests), clarified by centrifugation at
100000g for 45 min at 4 °C, purified on a Ni-NTA column,
washed with 10 column volumes of resuspension buffer and 20
mM imidazole, and eluted with resuspension buffer and 250
mM imidazole. Elution fractions were concentrated and
dialyzed against 50 mM Tris-HCl (pH 7.4), and the
concentration was determined from difference spectra using
an extinction coefficient of 91000 M−1 cm−1.21 The fraction of
P420 species never exceeded 5%. Molecular models for CYP
125A3 and 125A4 were generated using MODELER22 with the
structure of CYP125A1 in complex with 4-cholesten-3-one
(PDB entry 2X5W) as the template. For crystallography,
proteins were further purified by flow-through chromatography
on SP-Sepharose Fast-Flow (Amersham Biosciences) and
subsequent binding to Q-Sepharose Fast-Flow (Amersham
Biosciences), both equilibrated with 50 mM Tris-HCl buffer
(pH 7.5), and washed with 5 column volumes of equilibration
buffer. After being washed, the proteins were eluted with 0.5 M
NaCl in 50 mM Tris-HCl (pH 7.5). The protein was then
buffer exchanged into 50 mM potassium phosphate (pH 7.4).
Crystallization, Data Collection, and Model Refine-
ment. Single crystals of CYP124A3 W83Y were grown via
hanging-drop vapor diffusion in drops containing 100 nL of a
protein solution and 100 nL of a precipitant solution. The well
over which the crystals grew contained 0.1 M phosphate-citrate
buffer at pH 4.2 and 40% (v/v) PEG 600. To the protein
solution in the crystallization drop were added 90 nL of the
well solution and 10 nL of additive screen containing 0.33%
(w/v) 2,6-naphthalenedisulfonic acid disodium salt, 0.33% (w/
v) 2-aminobenezesulfonic acid, and 0.33% (w/v) m-benzene-
disulfonic acid disodium salt, and 0.02 M HEPES sodium at pH
6.8. Reddish-brown cube-shaped crystals grew within 14 days at
20 °C.
Data were collected at Advanced Light Source beamline 8.3.1
on a single crystal with approximate dimensions of 65 μm × 65
μm × 50 μm; 200 nL of 100% PEG 400 was added to the drop
containing the crystal, and the resultant drop was allowed to sit
for 1 min, after which time the crystal was pulled from the drop
and mounted directly in the cryostream. Two data sets were
collected, the first a low-resolution set at 1 s exposures,
followed by a second high-resolution set at 3 s per exposure,
and were processed at the beamline using Elves.23−26 Table 1
lists the relevant data collection and structure refinement
statistics.
The structure was determined by molecular replacement in
Phenix27 using a water and ligand free model of the previously
determined 2.0 Å structure of CYP125A3 (PDB entry 4APY).
Rigid body refinement was followed by the addition of the
protoporphyrin IX containing Fe and water molecules. TLS
refinement28 was performed using four groups: residues 2−119,
120−144, 145−280, and 281−411. Phosphate and citrate ions
were added to appropriately sized regions of positive electron
density. Several atoms of PEG 600 were added to clear positive
density in a position that indicated it was bound to the Fe(II)
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of the protoporphyrin IX and located within the cholesterol
binding pocket. Coordinates for this structure can be found in
the Protein Data Bank (entry 5DQN).
UV−Visible (UV−vis) Spectroscopy. UV−visible absorp-
tion spectra were recorded on a Cary UV−visible scanning
spectrophotometer (Varian) using a 1 cm path-length quartz
cuvette at ambient temperature in 50 mM potassium phosphate
buffer (pH 7.4) containing 150 mM NaCl. Spectral titrations
were performed using 3 μM P450 with the sequential addition
of substrates from concentrated stocks in methanol, with the
same solution added to the reference cuvette. Difference
spectra were recorded from 250 to 750 nm at a scanning rate of
120 nm/min. Data were fitted to a quadratic equation (eq 1) or
a Hill equation (eq 2) using GraphPad Prism
= + + − + +
−
A A K K{[S] [Et] [([S] [Et] )
(4[S][Et])] }/2[Et]
obs max S S
2
0.5
(1)
= × +A A S[S] / [S]n n nobs max 50 (2)
where Aobs is the observed absorption shift, Amax is the maximal
shift, KS (or S50 for the Hill equation) is the apparent
dissociation constant, [Et] is the total enzyme concentration,
[S] is the ligand concentration, and n is the Hill coefficient.
Assays were completed in triplicate, and error bars represent
the standard error.
Steady-State Kinetic Studies and Product Analysis.
Enzymes (0.5 or 3 μM) were preincubated for 5 min at ambient
temperature with substrate in 50 mM potassium phosphate
(pH 7.4) containing 0.05% (w/v) methyl-β-cyclodextrin, 150
mM NaCl, and 10 mM MgCl2. Reactions were initiated by
adding 100 mM NADPH, 1 μM spinach ferredoxin, 0.2 unit
mL−1 spinach ferredoxin-NADP+ reductase, 0.1 mg mL−1
bovine liver catalase, and an NADPH-regenerating system
consisting of 0.4 unit mL−1 glucose-6-phosphate dehydrogenase
and 5 mM glucose 6-phosphate. Aliquots of 50 μL were taken
between 0 and 30 min and quenched with 150 μL of
acetonitrile containing 0.1% formic acid (FA) and 10 μM 1,4-
cholestadiene-3-one as an internal standard. The reaction
mixtures were centrifuged at 10000g for 4 min. Product
formation was found to be linear with protein concentration
and reaction time. For reactions with cholesterol or 7α-
hydroxycholesterol, reactions were allowed to proceed for 45
min at ambient temperature, followed by the addition of 1 μL
of cholesterol oxidase (1 UN/μL) and incubation for an
additional 45 min at ambient temperature before analysis.
For quantification of the products, the reactions were
analyzed by high-performance liquid chromatography
(HPLC) using an Agilent Series 1200 HPLC system and a
reverse phase C18 column (Waters Xterra C18, 3.5 μm, 2.1
mm × 50 mm). For the 4-cholesten-3-one and cholesterol
reactions, the samples were eluted isocratically at a flow rate of
0.5 mL/min (solvent A, H2O and 0.1% formic acid; solvent B,
CH3CN and 0.1% formic acid) with a gradient starting at 70%
B for 1 min and the solvents ramped to 100% B over 11 min.
The elution was maintained at 100% B until 14 min and then
ramped back to 70% B within 1 min, followed by equilibration
at the same composition for 2 min before the next run. The
elution was monitored at 240 nm. For the 7α-hydroxy-4-
cholesten-3-one and 7α-hydroxycholesterol reactions, the
samples were eluted isocratically at a flow rate of 0.5 mL/
min (solvent A, H2O and 0.1% formic acid; solvent B, CH3CN
and 0.1% formic acid) with a gradient starting at 5% B for 3 min
and the solvents ramped to 95% B over 11 min. The elution
was maintained at 95% B until 16 min and then ramped back to
5% B within 0.1 min, followed by equilibration for 6 min. The
elution was monitored at 240 nm.
To determine the KM values, the data points were fitted to a
quadratic equation (eq 3) or a Hill equation (eq 4) using
GraphPad Prism
= + + − + +
−
k k K K{[S] [Et] [([S] [Et] )
(4[S][Et])] }/2[Et]
obs max M M
2
0.5
(3)
= × +k k S[S] / [S]n n nobs max 50 (4)
where kobs is the product forming rate determined at any ligand
concentration, kmax is the maximal rate, KM (or S50 for the Hill
equation) is the substrate concentration at which the half-
maximal rate is achieved, [Et] is the total enzyme concentration
used, [S] is the ligand concentration, and n is the Hill
coefficient. Assays were completed in triplicate, and error bars
represent the standard error.
■ RESULTS
Spectroscopic Properties of CYP189A1. Previous work
from our laboratory revealed the ability of the Msmeg
Δcyp125a3/Δcyp142a2 double knockout to utilize cholesterol
as a carbon source,14 unlike a similar mutant of Mtb that was
unable to grow on cholesterol in vitro.6 Microarray analysis of
the Msmeg mutant showed the presence of a single additional
cy tochrome P450-encoding gene , MSMEG_4829
(CYP189A1), that was upregulated in response to cholester-
ol.14 With no ortholog in the Mtb genome, we hypothesized
that CYP189A1 might be responsible for the Msmeg double
mutant’s ability to grow on cholesterol. CYP189A1 was
therefore cloned and expressed (see Experimental Procedures)
and tested for its ability to oxidize cholesterol. The UV−visible
spectrum of the protein was that of a classical, low-spin-state
P450 enzyme with a Soret maximum at 419 nm, which shifted
to 421 nm in the presence of the type II ligand econazole
(Figure 1A). Reduction with sodium dithionite and binding of
Table 1. Data and Structure Refinement Statistics
Data Collection
space group I41
unit cell [a, c (Å)] 108.566, 118.715
limiting resolution (Å) 2.262
total no. of reflections 63505
no. of unique reflections 32185
I/(I) 19.37
completeness (%) 99.67
Rmerge (Å) 4.274 (52.72)
Structure Refinement
resolution range (Å) 80.25−2.262
Rwork 0.1646 (0.3166)
Rfree 0.2088 (0.3460)
root-mean-square deviation for bond lengths (Å) 0.004
root-mean-square deviation for bond angles (deg) 0.80
no. of protein residues 410
no. of waters 86
no. of ligand atoms 86
average isotropic B factor (Å2)
protein atoms 63.3
solvent atoms 57.3
ligand atoms 70.6
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carbon monoxide revealed a nearly 100% population of the
P450 species, which gradually decayed into the inactive P420
form over the course of 20 min (Figure 1A, inset). However,
binding of the proposed substrates cholesterol and 4-cholesten-
3-one failed to induce the classical substrate type I binding
spectral shift of the Soret peak (Figure 1A), or any other
changes in the Soret peak that could be attributed to ligand
binding, and oxidation assays revealed no product formation
upon incubation of the enzyme with either proposed substrate
in the presence of suitable electron donor partners (data not
shown). Thus, CYP189A1 is unlikely to be responsible for the
Msmeg double mutant’s residual ability to utilize cholesterol.
Additional small molecules, including various terpenes, fatty
acids (saturated and unsaturated, single, and branched chain),
and polycyclic hydrocarbons, also failed to show any indication
of being substrates for this enzyme.
Spectroscopic Properties of CYP125A4 and Oxidation
of 4-Cholesten-3-one. Further analysis of the Msmeg genome
led us to investigate CYP125A4 (MSMEG_3524), a gene not
upregulated in response to cholesterol but that shares a high
degree of sequence homology (>60%) with the CYP125A3
gene (MSMEG_5995). Cloning, expression, and purification of
MSMEG_3524 enabled the spectroscopic characterization of
CYP125A4, which displayed characteristics similar to those of
the previously studied CYP125 enzymes. In the resting state,
CYP125A4 was observed to be in a mixture of the low- and
high-spin states, characterized by their respective Soret peaks at
414 and 393 nm (Figure 1B), although with a higher fraction of
the resting enzyme in the low-spin state than was observed for
its homolog CYP125A3.14 Binding of type II ligand econazole
shifted the Soret peak to 421 nm. Reduction of CYP125A4 with
sodium dithionite followed by binding of carbon monoxide
revealed a formation of the P450 species slower than that
observed with CYP189A1, with a small fraction of the inactive
P420 species also being concurrently formed (Figure 1B, inset).
The difference is most likely due to slower reduction of the
CYP125A4 enzyme by sodium dithionite. These observations
are similar to those previously obtained with CYP125A3.
Addition of cholesterol or 4-cholesten-3-one did induce a
partial shift to the type I high-spin species (Figure 1B), and
while both substrates were oxidized to form the C-26 alcohol
product, on the basis of the comparison of the product
retention time with that of the CYP125A1 reaction product, the
overall rate of oxidation by CYP125A4 (KM = 15.6 ± 3.6 μM;
Vmax = 0.08 ± 0.01 min
−1) for 4-cholesten-3-one was
approximately 20 times slower than that previously reported
for CYP125A3 (Vmax = 1.8 ± 0.1 min
−1) (Figure 1C).14
Structural Analysis of CYPs 125A3 and 125A4 and
Point Mutants. In search of insight into the reduced activity
toward 4-cholesten-3-one observed with CYP125A4, we
generated homology models of both CYP125A3 and
CYP125A4 using the substrate-bound structure of the Mtb
ortholog CYP125A1 (PDB entry 2X5W). Although the ligand
free structure of CYP125A3 was available as a model, the
ligand-bound structure of CYP125A1 revealed conformational
changes in the enzyme relative to its ligand free structure,
making the ligand-bound Mtb ortholog a more suitable model
for analyzing protein−ligand interactions.6 The bulky trypto-
phan (W83) in the CYP125A3 sequence was observed to be
positioned adjacent to C-7 of the 4-cholesten-3-one substrate.
In CYP125A4 this residue is replaced with a smaller tyrosine
Figure 1. UV−visible spectra for (A) CYP189A1 (3 μM) and (B) CYP125A4 (3 μM) without a ligand (), with 50 μM 4-cholesten-3-one (−−−),
and with 50 μM econazole (---). The inset shows CO difference spectra after 2 min (---) and 20 min (). (C) Fit for the CYP125A4 oxidation rate
of 4-cholesten-3-one to the quadratic binding equation (kcat/KM = 0.002 μM
−1 s−1).
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(Y87) and in the original CYP125A1 structure with a
phenylalanine (F100).
Generation of the W83Y mutation in CYP125A3 and
determination of the crystal structure (PDB entry 5DQN)
showed that the side chain volume change sufficiently increases
the size of the binding pocket such that it mimics that found in
the CYP125A1 structure 2X5W. This change allows the 7α-
hydroxycholesterol ligand greater access to the active site in the
mutant than in the wild-type enzyme. Using the discrete
volume determination method employed by 3V, the Voss
Volume Voxelator,29 and with the probe radius set to 1.5 Å, the
channel volume in the CYP125A3 W83Y structure is found to
be enlarged versus that of the wild-type CYP125A3 structure by
32 Å3, 22 Å3 of which can be directly attributed to the smaller
tyrosine side chain.30 Using similar measurement techniques,
the 2X5W CYP125A1 structure is found to have a channel
volume that is intermediate between those of the two
CYP125A3 structures, as shown in Table 2. Alignment of the
secondary structures of the three proteins using UCSF
Chimera31,32 reinforces the hypothesis that cholesterol faces
steric clashes with the tryptophan in wild-type CYP125A3 that
are not present in the CYP125A1 structure and would not be
seen in the CYP125A3 W83Y mutant. As shown in Figure
2B,32,33 the bound cholesterol in CYP125A1 structure 2X5W,
when modeled into the binding pocket of CYP125A3 structure
4APY, clashes with the Trp83 side chain. When mutated to
Tyr83 as in structure 5DQN and shown in Figure 2C, the
modeled cholesterol fits much like it does as reported in the
2X5W structure (Figure 2A). Figure 3 illustrates the shape of
the binding pocket of the CYP125A3 W83Y mutant, with the
ligand 4-cholesten-3-one modeled into the active site.
Binding and Oxidation of 7α-Hydroxysterol Deriva-
tives. To test the impact of this residue on substrate selectivity,
we examined the ability of both isoforms to bind 7α-
hydroxycholesterol and to oxidize 7α-hydroxy-4-cholesten-3-
one. CYP125A3 underwent a sigmoidal reverse type I spin
conversion back toward the low-spin species upon binding of
7α-hydroxycholesterol (S50 = 32.9 ± 4.7 μM; n = 1.7 ± 0.2)
(Figure 4A,B) but failed to oxidize 7α-hydroxy-4-cholesten-3-
one. CYP125A4 bound 7α-hydroxycholesterol as a typical type
I substrate (KS = 8.7 ± 0.5 μM) (Figure 4C,D) and readily
oxidized 7α-hydroxy-4-cholesten-3-one (KM = 4.1 ± 1.2 μM;
Vmax = 0.39 ± 0.02 min
−1) at rates much higher than the rates
with 4-cholesten-3-one (Figures 1C and 5A).
Characterization of the two single point mutants, CYP125A3
W83Y and CYP125A4 Y87W, resulted in a partial reversal of
each enzyme’s substrate profile. CYP125A3 W83Y had
drastically reduced activity toward 4-cholesten-3-one (KM =
24.1 ± 7.8 μM; Vmax = 0.02 ± 0.01 min
−1) (Figure 5A), with
rates lower than that of WT CYP125A4, while the CYP125A4
Y87W mutant showed increased activity toward 4-cholesten-3-
one (S50 = 28.3 ± 3.4 μM; n = 1.9 ± 0.3) (Figure 5A), albeit
with sigmoidal kinetics. For 7α-hydroxy-4-cholesten-3-one,
CYP125A4 Y87W showed greatly reduced activity relative to
the WT enzyme (KM = 5.1 ± 1.3 μM; Vmax = 0.16 ± 0.01
min−1) (Figure 5B), while CYP125A3 W83Y showed low
activity with small amounts of product being formed after
incubation with this substrate for 90 min as well as with 7α-
hydroxy-4-cholesten-3-one (Figure 5C).
CYP125A1, the primary cholesterol 26-hydroxylase in Mtb,
also catalyzes the 26-hydroxylation of 7α-hydroxy-4-cholesten-
3-one (Figure 5D). This is consistent with the crystal structure
of the complex of 4-cholesten-3-one with the protein,6 which
reveals a cavity in the structure that could readily accommodate
a 7α-hydroxy substituent (Figure 2A).
Taken together, these results show the critical role of a single
residue, Trp or Tyr, in determining the alternate substrate
profiles of the two CYP125 enzymes encoded in the Msmeg
genome, and how these closely related enzymes have
Table 2. Binding Pocket Volumes and Contact Statistics
4APY 5DQN 2X5W
cavity volume (Å3)a 2318 2350 2334
contacts (Å)b W83:2.45 Y83:4.03 F100:3.97
aVoxel size of 0.5 Å; probe radius of 1.5 Å.8 bShortest atomic distance
to 4-cholesten-3-one in binding position found in 2X5W.
Figure 2. Aligned binding pockets of (A) CYP125A1 (2X5W), (B)
wild-type CYP125A3 (4APY), and (C) CYP125A3 W83Y (5DQN).
The 4-cholesten-3-one ligand (blue) is shown overlaid into the
CYP125A3 active sites, showing steric clashes with Trp83 in the wild
type (B) and elimination of clashes in the W83Y mutant (C).
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overlapping yet distinct and complementary functions in this
mycobacterial species.
■ DISCUSSION
The degradation of cholesterol and 4-cholesten-3-one is
catalyzed in Mtb by both CYP125A1 and CYP142A1.8
However, we recently reported that the structures of CYP142
enzymes, which have an uncapped active site, allow them also
to oxidize cholesterol esters, whereas CYP125 enzymes, which
have a capped active site, cannot catalyze this oxidation.34 A
similar difference exists between CYP125A3 and CYP142A2,
the previously reported orthologs from Msmeg. In contrast to
Mtb, deletion of these two enzymes impaired, but did not fully
prevent, in vitro growth of Msmeg on cholesterol as the sole
carbon source.14 This implies the existence of an alternative
pathway for cholesterol utilization. On the basis of its
upregulation in response to cholesterol, CYP189A1 was first
examined to determine if it had the required cholesterol
metabolizing activity. However, our biochemical studies
demonstrated that neither cholesterol nor 4-cholesten-3-one
is a substrate for this enzyme. Our attention therefore turned to
CYP125A4, a second CYP125 enzyme from Msmeg. As
reported here, this enzyme has low cholesterol oxidizing
activity in addition to a much stronger ability to oxidize sterols
with a C-7 substituent. CYP125A4 thus broadens the ability of
Msmeg, an environmental mycobacterium, to utilize diverse
sterol substrates as carbon sources.
The structural constraints that control the ability to oxidize
7α-hydroxycholesterol have been investigated by comparing the
protein sequences and activities of two members of the
CYP125 family, CYP125A3, which readily oxidizes cholesterol
but has very low activity for 7α-hydroxycholesterol, and
CYP125A4, which strongly favors oxidation of 7α-hydrox-
ycholesterol over that of cholesterol. Homology modeling
suggested the presence of a bulky tryptophan rather than a
tyrosine (or the phenylalanine of CYP125A1) at a position
adjacent to C-7 of the sterol in the substrate−protein complex
is largely responsible for the weakened ability of CYP125A3 to
oxidize 7α-hydroxycholesterol. Generation of the CYP125A3
W83Y and CYP125A4 Y87W mutants confirmed the
importance of this residue by partially reversing the substrate
specificity for each enzyme (Figure 5), and structural
comparison of CYP125A3 wild-type and mutant active sites
Figure 3. Cross-sectional view of the substrate access channel of
CYP125A3 W83Y (5DQN) with 4-cholesten-3-one colored cyan and
heme colored red. Generated using UCSF Chimera.31,32
Figure 4. (A) Hill equation fit of (B) UV−visible spectroscopic changes induced by 7α-hydroxycholesterol binding to CYP125A3 (S50 = 32.9 ± 4.7
μM; n = 1.7 ± 0.2) and (C) quadratic binding equation fit of (D) UV−visible spectroscopic changes induced by 7α-hydroxycholesterol binding to
CYP125A4 (KS = 8.7 ± 0.5 μM).
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(Figure 2), which revealed a steric block preventing access for
the substrate in the wild-type structure.
There are no obvious additional biological implications of the
ability of CYP125A4 in Msmeg to oxidize 7α-hydroxycholester-
ol. However, the same is not true inMtb, as 26-hydroxylation of
7α-hydroxycholesterol yields 7α,26-dihydroxycholesterol, a
molecule that is a potent modulator of the host immune
system.16,17 These results suggest that there may be a signaling
interaction between Mtb and its human host that impacts the
pathogenicity of the mycobacterium. The reality of such an
interaction will depend on the concentration of 7α-hydrox-
ycholesterol available to the mycobacterium and the extent to
which it exports the 7α,26-dihydroxycholesterol metabolite
once it is formed.
The metabolism of cholesterol by Mtb has been linked to
virulence of infection1 and has been suggested as a target
pathway for therapeutics.7 While Msmeg, which has been used
as a model system for understanding Mtb, shares a similar
cholesterol metabolic pathway with its mycobacterial relative,
this study illustrates subtle differences in the way these two
species have adapted to respond to cholesterol. These
differences must be considered when evaluating antimycobac-
terial compounds that target the cholesterol metabolizing
pathway.
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Figure 5. Fits of (A) 4-cholesten-3-one oxidation by CYP125A3 W83Y (solid line; kcat/KM = 0.01 μM
−1 s−1) and CYP125A4 Y87W (dashed line;
kcat/KM = 0.001 μM
−1 s−1) and (B) 7α-hydroxy-4-cholesten-3-one oxidation by CYP125A4 (solid line; kcat/KM = 0.19 μM
−1 s−1) and CYP125A4
Y87W (dashed line; kcat/KM = 0.011 μM
−1 s−1). HPLC traces of 7α-hydroxy-4-cholesten-3-one oxidation by (C) CYP125A3 at the 0 min time point
(small dashes) and 90 min time point (solid line) and CYP125A3 W83Y at the 90 min time point (large dashes) and (D) CYP125A1 at the 0 min
time point (solid line) and 90 min time point (dashed line). The 10.7 min peak is the product 7α,26-dihydroxy-4-cholesten-3-one, and the substrate
peak, 7α-hydroxy-4-cholesten-3-one, is at 14 min.
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